About Contact Us Careers

Prednisone Market Size and Forecast, by Disease (Rheumatology Indications, Skin Allergies, Endocrinology, Gastroenterology, Acute Respiratory Disease); Application (Hospital, Clinic, Recovery Center) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5384
  • Published Date: Nov 26, 2025
  • Report Format: PDF, PPT

Prednisone Market Outlook:

Prednisone Market size was over USD 6.6 billion in 2025 and is anticipated to cross USD 11.06 billion by 2035, growing at more than 5.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of prednisone is assessed at USD 6.91 billion.

Prednisone Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The major element to influence the market expansion is the surge in the prevalence of skin disease. According to the World Health Organization, it has been estimated that 1.8 billion people worldwide suffer from skin disorders at any given moment. Skin infections, which may be caused by bacteria, viruses, fungi, or parasites, are the most common cause of illness in tropical and low-resource environments.

As a result, there have been growing initiatives such as the launch of new prednisone medication and spreading awareness among people for the same by the government in such an environment to tackle the issue of skin disease. This is since it is estimated that skin disease might also further increase the prevalence of death. Therefore, the market demand for prednisone is set to grow over the coming years.

Key Prednisone Market Insights Summary:

  • Regional Highlights:

    • North America is estimated to secure a 35% revenue share in the prednisone market by 2035, fostered by the rising prevalence of asthma in the region.
    • The Asia Pacific is anticipated to expand significantly through 2035, stimulated by increasing disease incidence associated with limited physical activity and a surge in kidney disorder cases.

  • Segment Insights:

    • The skin allergies segment is projected to command a 40% share of the global prednisone market by 2035, supported by the escalating incidence of acne among teenagers.
    • The hospital segment is expected to capture about 50% share over the coming years, underpinned by rising healthcare investments and growing patient admissions.

  • Key Growth Trends:

    • Surge in COVID 19 Cases
    • Rise in Prevalence of Irritable Bowel

  • Major Challenges:

    • Side Effects Related to Prednisone
    • Lack of Awareness Among People Regarding Prednisone

  • Key Players: Pfizer Inc., Merck & Co., Inc., GSK plc, Sanofi, AstraZeneca, Eli Lilly and Company, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd.

Global Prednisone Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 6.6 billion
    • 2026 Market Size: USD 6.91 billion
    • Projected Market Size: USD 11.06 billion by 2035
    • Growth Forecasts: 5.3%

  • Key Regional Dynamics:

    • Largest Region: North America (35% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Germany, Japan, United Kingdom
    • Emerging Countries: India, Brazil, South Korea, Mexico, Indonesia

    • Last updated on : 26 November, 2025

Growth Drivers

  • Surge in COVID-19 Cases - Around the world coronavirus (COVID-19) cases reported close to 767 million as of June 13, 2023. Furthermore, a significant number of patients display severe COVID-19 symptoms, which usually involve low blood oxygen, pneumonia-like symptoms, and severe respiratory distress. Excessive immune system stimulation is experienced by those with severe or serious COVID-19, and this may have detrimental effects on their health. Prednisolone helps to reduce this overstimulation by regulating the immune system's responses to make sure they are both beneficial and do not damage the person. According to the WHO, the readily accessible data, containing information from 7000 individuals with low oxygen levels across 8 clinical trials, demonstrate that corticosteroids lower the number of fatalities from COVID-19. According to the results of these studies, treating patients with severe COVID-19 with corticosteroids during their illness decreases mortality by 20%. Eliminating the requirement for ventilation—which involves placing patients on a machine to assist with breathing—has other advantages.
  • Rise in Prevalence of Irritable Bowel - Scholars have examined the purpose of inflammation in the condition known as irritable bowel syndrome (IBS). According to studies, IBS symptoms might be triggered by inflammation brought on by an infection, and some people with the condition might suffer from persistent inflammation. As a consequence, prednisone use is growing since it has anti-inflammatory properties.
  • Growth in Geriatric Population - Older people are more prone to increased risk of age-related liver, renal, or cardiac issues which could further cause fatality among them. The physiological changes brought on by ageing, weakened immune systems, and multimorbidity render older adults greater vulnerable to infections and increase their risk of experiencing severe illness along with serious complications. These factors are just a few of the reasons why different diseases have a greater impact on older people. Additionally, elderly people are far more probable to develop a serious illness after contracting COVID-19. Hence, the importance of prednisone is growing among geriatric population.

Challenges

  • Side Effects Related to Prednisone – When prednisone is taken in high quantity its further cause various side effects. Common side effects include weight gain, mild mood change, insomnia, and more. However, there could be more severe side effects. An extremely irritable stomach or feeling ill (vomiting), severe vertigo or fainting, muscle weakness, extreme exhaustion, mood swings, appetite loss, and weight loss all serve as indicators of adrenal gland side effects. Furthermore, when children and teenagers take higher amounts of prednisolone over an extended period of time, their normal growth may be slowed down.
  • Lack of Awareness Among People Regarding Prednisone – A Large number of people are unaware of the benefits of this medication. Furthermore, in low income countries since the healthcare sector lacks development, this medication is not known to all and unaware about the quantity it should be used. Hence, a large number of time many people fall prey to its side effects. Therefore, this factor could impede the growth in the revenue of the market.
  • High Price of Prednisone

Prednisone Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

5.3%

Base Year Market Size (2025)

USD 6.6 billion

Forecast Year Market Size (2035)

USD 11.06 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Prednisone Market Segmentation:

Disease Segment Analysis

The skin allergies segment is projected to hold 40% share of the global prednisone market by 2035. There has been a growing prevalence of acne all across the globe. A lot of people have acne, and it affects about 8% of the global population, according to research estimates. Additionally, cases of acne are highly seen among teenagers. This prevalent skin condition, which affects over 84% of teenagers, is characterized by clogged pores (whiteheads and blackheads), uncomfortable pimples, and occasionally hard, deep lumps on the face, neck, shoulders, chest, back, and upper arms. Hence, with the growing population of teenagers, the segment is set to have significant growth over the forecast period.

Application Segment Analysis

Prednisone market from the hospital segment is poised to generate the highest revenue share of about 50% over the coming years. This could be owing to the growing investment made in the healthcare sector. Additionally, the number of patients getting admitted to hospitals is also surging. Hospitalized individuals who have a wide range of serious illnesses, such as those with neurological, pulmonary, and cardiovascular diseases, might benefit from steroids. Hospitals provide care for a wide variety of illnesses through dermatology medical devices. Hospitalist physicians typically have a focus on internal medicine, pediatrics, or family practice. They have the resources to handle complex medical problems as well as the knowledge to assist with routine ones. Moreover, there has been an increase in advancement in hospitals and a wide array of medicines are available here.

Our in-depth analysis of the global prednisone market includes the following segments:

         Disease

  • Rheumatology Indications

  • Skin Allergies

  • Endocrinology

  • Gastroenterology

  • Acute Respiratory Disease

          Application

  • Hospital

  • Clinic

  • Recovery Center
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Prednisone Market - Regional Analysis

North American Market Insights

North America industry is estimated to hold largest revenue share of 35% by 2035. This growth could be influenced by the rising prevalence of asthma in this region. Asthma affects approximately 7% of Americans. About 19 million of them over 25 million are adults, while 6.1 million are children. Although illness prevalence varies and the majority of disease-related deaths take place in low-income nations, asthma remains a serious public health concern throughout the Americas. Additionally, globally, especially in the Americas, obesity has been linked with higher severity of asthma and asthma in children and adults. Some research indicates that obesity is more strongly associated with asthma outcomes in females. Leptin levels in cord blood are linked to asthma in Chilean infants born to obese mothers, and maternal obesity and diet have also been linked to asthma in children. All these factors which is boosting the prevalence of asthma are also predicted to dominate the market demand for prednisone in this region.

APAC Market Insights

The prednisone market in Asia Pacific is set to have notable growth during the forecast period. This growth of the market is predicted to rise on account of the lack of physical activity which has further given rise to the number of diseases in this region. Additionally, there has been a rise in the prevalence of kidney disorders in this region. In the eastern, southern, and southeast parts of Asia, up to 434.3 million people are affected by chronic kidney disease (CKD), with China and India accounting for the majority of cases (up to 299.9 million). Therefore, the growth of the market in this region is projected to flourish.

Prednisone Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Prednisone Market Players:

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck & Co., Inc.  
    • GSK plc  
    • Sanofi
    • AstraZeneca
    • Eli Lilly and Company
    • AbbVie Inc.
    • Bristol Myers Squibb Company 
    • F. Hoffmann-La Roche Ltd
    • Teva Pharmaceutical Industries Ltd.

Recent Developments

  • October 5, 2023: Pfizer Inc. declared that ABRILADA, an interchangeable biosimilar of Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA). All approved uses of ABRILADA are covered by the interchangeable designation, which also includes some patients with psoriatic arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
  • March 2, 2023: An ODAC meeting will be held by the U.S. Food and Drug Administration (FDA) to discuss the supplemental new drug application (sNDA) for LYNPARZA, which is intended to be used in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. AstraZeneca and Merck & Co., Inc., which are referred to as MSD outside of the United States and Canada, made this announcement. On marketed and experimental medications for use in cancer treatment, the ODAC offers the FDA unbiased, professional opinions and recommendations. Although the committee's recommendations are not legally binding, the FDA does take them into account.
  • Report ID: 5384
  • Published Date: Nov 26, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of prednisone is assessed at USD 6.91 billion.

The global prednisone market size was valued at around USD 6.6 billion in 2025 and is projected to grow at a CAGR of more than 5.3%, reaching USD 11.06 billion revenue by 2035.

North America is estimated to secure a 35% revenue share in the prednisone market by 2035, fostered by the rising prevalence of asthma in the region.

Key players in the market include Pfizer Inc., Merck & Co., Inc., GSK plc, Sanofi, AstraZeneca, Eli Lilly and Company, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd.

Prednisone Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos